Thromb Haemost 2021; 121(10): 1361-1366
DOI: 10.1055/s-0041-1725197
Stroke, Systemic or Venous Thromboembolism

Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study

Alessandro Arrigo
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Anna Crepaldi
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Chiara Viganò
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Emanuela Aragona
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Rosangela Lattanzio
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Giovanni Scalia
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Antonio Giordano Resti
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Francesca Calcagno
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Adelaide Pina
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Hassan Farah Rashid
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Francesco Bandello
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Maurizio Battaglia Parodi
1  Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
› Author Affiliations

Abstract

Retinal vein occlusion is the second most common retinal vascular pathology after diabetic retinopathy and a major cause of vision impairment. Nowadays, both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) can be well-managed by intravitreal treatments. However, considering the long-life expectance of the patients, few data are present in the literature about the very long-term outcome of CRVO and BRVO. The present study was an interventional, retrospective analysis of the morphological and functional long-term outcome of CRVO and BRVO patients, followed in an Italian referral center. We collected data from 313 eyes (178 CRVO eyes and 135 BRVO eyes). Mean follow-up was 45 ± 25 months (range 12–84 months). Both CRVO and BRVO eyes experience a significant visual acuity improvement secondary to anti-vascular endothelial growth factor/dexamethasone treatments (from 0.57 ± 0.25 to 0.41 ± 0.24 LogMAR in CRVO and from 0.53 ± 0.42 to 0.30 ± 0.41 LogMAR in BRVO, respectively) (p < 0.01). Also, central macular thickness (CMT) resulted significant recovery at the end of the follow-up (from 585.54 ± 131.43 to 447.88 ± 245.07 μm in CRVO and from 585.54 ± 131.43 to 447.88 ± 245.07 μm in BRVO, respectively) (p < 0.01). CRVO eyes received a mean of 10.70 ± 4.76 intravitreal treatments, whereas BRVO underwent 9.80 ± 5.39 injections over the entire 7-year follow-up. Our analyses highlighted different time points indicating the best obtainable improvement. This was the first year for CRVO (12-month follow-up) and the second year for BRVO (24-month follow-up). After these two time points, both visual acuity and CMT resulted stable up to the end of the follow-up. Ischemia was associated with significantly worse outcome.



Publication History

Received: 14 December 2020

Accepted: 23 January 2021

Publication Date:
11 March 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany